% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gwenzi:306579,
      author       = {T. Gwenzi$^*$ and D. Wankhede$^*$ and T. Yuan$^*$ and M.
                      Bhardwaj$^*$ and P. Schrotz-King$^*$ and S. C. Anker and B.
                      Schöttker$^*$ and M. Hoffmeister$^*$ and H. Brenner$^*$},
      title        = {{P}redicting colorectal cancer survival by combined
                      c-reactive protein and tumor immune score.},
      journal      = {npj precision oncology},
      volume       = {nn},
      issn         = {2397-768X},
      address      = {[London]},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2025-02620},
      pages        = {nn},
      year         = {2025},
      note         = {#EA:C070#LA:C070# / epub},
      abstract     = {We evaluated the joint relationship of post-operative
                      C-reactive protein (poCRP) and a tumor immune-cell-score
                      (IS) with overall survival (OS) and CRC-specific survival
                      (CSS) in 680 colorectal cancer (CRC) patients recruited in
                      Germany. CRP was assessed post-surgery while IS was derived
                      from CD3 + /CD8+ cell densities in tumor tissue. Patients
                      were categorized into four C-Reactive protein-Immune cell
                      Score (CRIS) groups: CRIS-1 (CRP-low/IS-high), CRIS-2
                      (CRP-low/IS-low), CRIS-3 (CRP-high/IS-high), and CRIS-4
                      (CRP-high/IS-low). Associations of CRIS with survival were
                      assessed using Cox regression, and quantified by hazard
                      ratios with $95\%$ confidence intervals (HR, $95\%CI).$
                      Subgroup analysis by presence of non-metastatic disease and
                      time of blood draw in relation to adjuvant chemotherapy were
                      conducted. After a median follow-up of 9.6 (IQR, 4.6-14.6)
                      years, 214 $(31.5\%)$ patients died, 140 $(20.6\%)$ from
                      CRC. Patients in CRIS-4 category had worse prognosis
                      compared to CRIS-1 category $[HR(95\%CI):$ 2.01 (1.32-3.08)
                      and 2.60 (1.57-4.32) for OS and CSS, respectively]. These
                      associations were stronger for non-metastatic disease (OSHR
                      = 2.45, CSSHR = 4.49), as well as for patients with blood
                      collected after adjuvant chemotherapy (OSHR = 4.17, CSSHR =
                      6.62). Integrating post-operative systemic inflammation and
                      tumor immune characteristics may improve prognostic
                      stratification of patients receiving adjuvant chemotherapy
                      for non-metastatic CRC.},
      cin          = {C070 / C120 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41291131},
      doi          = {10.1038/s41698-025-01192-1},
      url          = {https://inrepo02.dkfz.de/record/306579},
}